The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

被引：7
|
作者：
Plasencia, Ch [1 ]
Pascual-Salcedo, D. [2 ]
Alcocer, P. [1 ]
Bonilla, M. G. [1 ]
Villalba, A. [1 ]
Peiteado, D. [1 ]
Arribas, F. [2 ]
Diez, J. [3 ]
Lopez-Casla, M. T. [2 ]
Martin-Mola, E. [1 ]
Balsa, A. [1 ]
机构：
[1] Paz Univ Hosp Idipaz, Dept Rheumatol, Paseo Castellana 261, Madrid 28046, Spain
[2] Paz Univ Hosp Idipaz, Immunol Unit, Madrid, Spain
[3] Paz Univ Hosp Idipaz, Stat Dept, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 11期
关键词：
Anti-TNF; Rheumatoid Arthritis; Treatment; IMMUNOGENICITY;
D O I：
10.1136/annrheumdis-2013-203353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1888 / 1890
页数：3
相关论文
共 50 条
  • [31] Improvement in hemoglobin in patients with rheumatoid arthritis treated with infliximab.
    Doyle, M. K.
    Rahman, M. U.
    Han, J.
    Baker, D.
    Giles, J. T.
    Bingham, C. O., III
    Bathon, J. M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S235 - S235
  • [32] OXIDATIVE STRESS STUDY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB
    Tomas, C.
    de Agustin, J. J.
    Erra, A.
    Arnal, C.
    Dominguez, C.
    Marsal, S.
    RHEUMATOLOGY, 2002, 41 : 93 - 93
  • [33] THE EARLY INFLIXIMAB LEVELS MONITORING CAN PREDICT THE DEVELOPEMENT OF ANTI-DRUG ANTIBODIES IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB
    Chamaida, P. -R.
    Pascual-Salcedo, D.
    Bonilla, M.
    Villalba, A.
    Lopez-Casla, M.
    Peiteado, D.
    Garcia-Carazo, S.
    Ramiro, S.
    Franco, K.
    Cajigas, D.
    Martin-Mola, E.
    Balsa, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 157 - 157
  • [34] Pharmocogenomic analysis of the effects of infliximab and the appearance of HACA (a neutralixing antibody against infliximab) in clinical treatment of rheumatoid arthritis.
    Matsubara, Tsukasa
    Funahashi, Keiko
    Ji, Guijin
    Baba, Masanori
    Sato, Hidenori
    Saji, Hiromi
    Emi, Mitsuru
    Ichien, Go
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S329 - S330
  • [35] The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
    Dwivedi, Ravi C.
    Dhindsa, Navjot
    Krokhin, Oleg V.
    Cortens, John
    Wilkins, John A.
    El-Gabalawy, Hani S.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (02)
  • [36] The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
    Ravi C Dwivedi
    Navjot Dhindsa
    Oleg V Krokhin
    John Cortens
    John A Wilkins
    Hani S El-Gabalawy
    Arthritis Research & Therapy, 11
  • [37] Fucosylation of serum α1-acid glycoprotein in rheumatoid arthritis patients treated with infliximab
    Olewicz-Gawlik, Anna
    Korczowska-Lacka, Izabela
    Lacki, Jan K.
    Klama, Kamilla
    Hrycaj, Pawel
    CLINICAL RHEUMATOLOGY, 2007, 26 (10) : 1679 - 1684
  • [38] Fucosylation of serum α1-acid glycoprotein in rheumatoid arthritis patients treated with infliximab
    Anna Olewicz-Gawlik
    Izabela Korczowska-Łącka
    Jan K. Łącki
    Kamilla Klama
    Paweł Hrycaj
    Clinical Rheumatology, 2007, 26 : 1679 - 1684
  • [39] METHOTREXATE REDUCED TNF BIOACTIVITY BY ANTI-INFLIXIMAB ANTIBODY PREVENTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB
    Denarie, D.
    Rinaudo, M.
    Thomas, T.
    Paul, S.
    Marotte, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 459 - 459
  • [40] CLINICAL CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENTS TO BE INTENSIFIED INFLIXIMAB THERAPY
    Oguma, A.
    Irino, K.
    Sawabe, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 946 - 946
12345